Welcome To The Mannkind HUB On AGORACOM Edit this title from the Fast Facts Section
Well at least he's honest...
In the contrast to the collective name “Big Pharma” which refers to all pharmaceutical fields I would propose a new term “Big Diabetes Pharma” – top 5 companies which monopolize the diabetes market: Novo Nordisk , Sanofi , MannKind, and the diabetes partnership of Bristol-Myers Squibb and AstraZeneca.
The diabetes treatment business is booming. According to the Centers for Disease Control and Prevention, 25.8 million Americans are affected by diabetes. That's more than 8% of the U.S. population. S&P's Rating Services estimates that the global diabetes market will grow to 280 million people in the next 20 years, elevating sales of diabetes-related treatments from $35 billion to $58 billion.
Well, monopoly and cartel are extremely profitable systems and they are basically the main target in business wars. Those 5 companies are clearly winners! My congratulations! But what about the diabetes patients? Who cares?!
Please
login
to post a reply